Homology Medicines Inc. (NASDAQ: FIXX) started the day on April 07, 2021, with a price decrease of -22.80% at $7.18. During the day, the stock rose to $7.93 and sunk to $7.18 before settling in for the price of $9.30 at the close. Taking a more long-term approach, FIXX posted a 52-week range of $8.70-$19.40.
Nevertheless, stock’s Earnings Per Share (EPS) this year is -13.60%. This publicly-traded company’s shares outstanding now amounts to $48.05 million, simultaneously with a float of $37.84 million. The organization now has a market capitalization sitting at $354.62 million. At the time of writing, stock’s 50-day Moving Average stood at $11.19, while the 200-day Moving Average is $11.71.
It is quite fundamental to gauge the extent of the productivity of the business which is accounted for 205 workers. It has generated 13,180 per worker during the last fiscal year. Meanwhile, its income per employee was -627,776. The stock had 6.76 Receivables turnover and 0.01 Total Asset turnover. For the Profitability, stocks operating margin was -4820.98 and Pretax Margin of -4762.92.
Homology Medicines Inc. (FIXX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Homology Medicines Inc.’s current insider ownership accounts for 0.30%, in contrast to 73.10% institutional ownership. According to the most recent insider trade that took place on Feb 08, this organization’s CFO & Treasurer sold 13,500 shares at the rate of 14.25, making the entire transaction reach 192,425 in total value, affecting insider ownership by 0. Preceding that transaction, on Feb 02, Company’s See Remarks sold 500 for 13.00, making the whole transaction’s value amount to 6,500. This particular insider is now the holder of 0 in total.
Homology Medicines Inc. (FIXX) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 12/30/2020, the organization reported -$0.62 earnings per share (EPS) for the three months, surpassing the consensus estimate (set at -$0.68) by $0.06. This company achieved a net margin of -4762.92 while generating a return on equity of -56.63. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.69 per share during the current fiscal year.
Homology Medicines Inc.’s EPS decrease for this current 12-month fiscal period is -13.60% and is forecasted to reach -2.60 in the upcoming year.
Homology Medicines Inc. (NASDAQ: FIXX) Trading Performance Indicators
Let’s observe the current performance indicators for Homology Medicines Inc. (FIXX). It’s Quick Ratio in the last reported quarter now stands at 9.70. The Stock has managed to achieve an average true range (ATR) of 0.65. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 131.34.
In the same vein, FIXX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.81, a figure that is expected to reach -0.67 in the next quarter, and analysts are predicting that it will be -2.60 at the market close of one year from today.
Technical Analysis of Homology Medicines Inc. (FIXX)
If we take a close look at the recent performances of Homology Medicines Inc. (NASDAQ: FIXX), its last 5-days Average volume was 1.53 million that shows progress from its year to date volume of 0.47 million. During the previous 9 days, stock’s Stochastic %D was recorded 34.29% While, its Average True Range was 0.68.
Raw Stochastic average of Homology Medicines Inc. (FIXX) in the period of the previous 100 days is set at 0.00%, which indicates a major rise in contrast to 0.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 113.91% that was higher than 77.48% volatility it exhibited in the past 100-days period.